Princeton, NJ—January 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals.
ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. ISPOR Global Health Care Systems Road Maps can benefit a variety of stakeholders—such as health care decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for health care technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific health care experts and are updated over time to reflect changes in the country’s health care delivery system.
According to the newly published ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals, all Danish citizens are covered by national health insurance. The Danish Medicines Agency decides the reimbursement status for pharmaceutical products and is responsible for legislation concerning pharmaceuticals, medical devices, and clinical trials. Marketing authorization in Denmark is regulated according to European Union (EU) regulation by the European Medicines Agency and does not differ in Denmark from that of other European countries. The total public health care expenditure in Denmark for 2014 were 102,569 billion Danish Krone (DKK) and pharmaceutical spending constituted 12.4% of regional health care expenses.
The ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals may be found here. Other ISPOR Global Health Care Systems Road Maps published in 2015 include:
Additional information on all of the ISPOR Tools for Health Care Decision Makers may be found here.